Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493662 · ClinicalTrials.gov registry record · Phase 4
Cross-Over Evaluation of Two Lubricating Eye Drops
A Phase 4 study, sponsored by Innovative Medical.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00493662: Completed Phase 4 study, sponsored by Innovative Medical.
NCT00493662 is a Phase 4 study that has completed, run by Innovative Medical. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00493662, a Phase 4 study, has completed, sponsored by Innovative Medical.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
To evaluate the efficacy of two lubricating eye drops for the treatment of dry eye signs and symptoms.
Interventions
- DRUG sodium chloride
- DRUG Polyethylene Glycol 400 0.4%
- DRUG Propylene Glycol 0.3%
- DRUG 0.15% sodium Hyaluronate
- DRUG sodium phosphate monobasic
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 4 |
What the finished NCT00493662 record still lists
NCT00493662 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which sodium chloride is the first listed.
NCT00493662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00493662 about?
NCT00493662 is a clinical study titled "Cross-Over Evaluation of Two Lubricating Eye Drops". To evaluate the efficacy of two lubricating eye drops for the treatment of dry eye signs and symptoms.
What is the current status of trial NCT00493662?
This trial is currently completed. It is a Phase 4 study.
What interventions are being tested in trial NCT00493662?
The interventions under investigation include: sodium chloride (DRUG), Polyethylene Glycol 400 0.4% (DRUG), Propylene Glycol 0.3% (DRUG), 0.15% sodium Hyaluronate (DRUG), sodium phosphate monobasic (DRUG).
Who is sponsoring clinical trial NCT00493662?
This trial is sponsored by Innovative Medical, which has 44 total clinical trials registered on ClinicalTrials.gov.